Immunochemotherapy of human cancer.
D000208:Acute Disease; D000276:Adjuvants, Immunologic; D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy; D007939:Leukemia L1210 / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D007166:Immunosuppressive Agents; D003561:Cytarabine; D014750:Vincristine; D011241:Prednisone